Chemokine receptor repertoire reflects mature T-cell lymphoproliferative disorder clinical presentation

Moura, João; Rodrigues, Jaime; Santos, Ana Filipa L.O.M.; Teixeira, Maria dos Anjos; Queirós, Maria Luı́s; Santos, Maria do Carmo; Gonçalves, Marta; Fonseca, Sónia; Laranjeira, Carla; Rodrigues, António Silva; Júnior, Esmeraldina; Ribeiro, Fernanda Machado; Acosta, Maria João; Lima, Margarida

doi:10.1016/j.bcmd.2008.08.002

Cited by 7 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Melanoma cells have been found to secrete elevated amounts of CXCL-1(Gro-α), facilitating tumor growth 70,71 . CXCL1 binds CXCR2 receptor, which is expressed mainly by neutrophils but not by T cells, except on CD4+ T cells in large granular lymphocytic leukemia 72 . TILs have been engineered to express CXCR2 receptor, and transduced cells were shown to be able to migrate towards CXCL1 chemokine in vitro 71 .…”

Section: Targeting Tils To the Tumor: Gene Modification Of Infused T mentioning

confidence: 99%

Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy

Bernatchez

Radvanyi

Hwu

2012

Seminars in Oncology

View full text Add to dashboard Cite

Metastatic melanoma is notoriously resistant to chemotherapy and radiotherapy regimens. The prospect for newly diagnosed metastatic melanoma patients is grim with a median survival of less than a year. Currently, the only therapies resulting in long term disease free intervals, high dose Interleukin-2 (IL-2) and more recently anti-CTLA-41, work through activation of the immune system. However, with both therapies the response rate is low. Advances in our knowledge of how the immune system interacts with cancer have led to a number of strategies to manipulate anti-tumor immune responses through immunotherapy. This review will focus on one avenue of immunotherapy using the transfer of T cells referred to as “Adoptive Cell Therapy” (ACT), which involves the ex vivo expansion of autologous tumor-specific T cells to large numbers that are ultimately transferred back to the patient to boost anti-tumor immunity. This approach has been shown to be effective in the treatment of virally induced cancers, as well as metastatic melanoma. Recent successes with ACT hold promise and further emphasize the tremendous potential benefit of harnessing the immune system in the fight against cancer.

show abstract

Section: Targeting Tils To the Tumor: Gene Modification Of Infused T mentioning

confidence: 99%

Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy

Bernatchez

Radvanyi

Hwu

2012

Seminars in Oncology

View full text Add to dashboard Cite

show abstract

“…17 T-cell large granular lymphocytic leukemia cells mainly express CXCR1 and CXCR2, whereas peripheral T-cell lymphoma cells usually express CCR4, CCR6, and CCR7. 18 CXCR3 was reported to be present in marginal zone lymphoma. 19 However, chemoattractants that stimulate the locomotion of BPDC are insufficiently known.…”

mentioning

confidence: 98%

Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm

Hashikawa¹,

Niino²,

Yasumoto³

et al. 2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…A disadvantage of this method is that currently used anti-TCR-Vb antibody panel does not absolutely prove clonality because it covers only about 70% of the TCR-Vb repertoire and a subset of monoclonal T-LGLs remains undetected [23]. Moura et al [25 ] demonstrated that expression of inflammatory chemokine receptors on neoplastic T cells is an additional tool in T-LGL leukemia differential diagnosis and has an impact on clinical presentation. High expression of late inflammatory interleukin-8 receptors (CXCR1 and CXCR2) and absence of CCR4 or CCR7 (organ homing receptors) indicate T-LGL leukemia.…”

Section: Assessment Ofmentioning

confidence: 97%